Integer Holdings Corporation Financial Performance Update
Integer Holdings Corporation (NYSE: ITGR) recently shared its results for the third quarter ending September 26, 2025. The company continues to show resilience and growth in a competitive market.
Q3 2025 Highlights
In the latest quarter, Integer achieved significant advancements compared to the same period in 2024:
- Sales rose by 8%, reaching $468 million, driven largely by organic growth of 7%.
- GAAP operating income was reported at $56 million, a slight decrease from $58 million in 2024, while Non-GAAP adjusted operating income surged by 14% to $86 million.
- GAAP income from continuing operations increased to $40 million, a 9% growth, whereas Non-GAAP adjusted net income soared to $63 million, reflecting a 27% increase.
- GAAP diluted earnings per share (EPS) enhanced to $1.11, marking a 10% rise, and the Non-GAAP adjusted EPS elevated to $1.79, a 25% increase.
- Adjusted EBITDA saw an 11% rise, reaching $106 million.
- Total debt rose by $204 million to $1.194 billion primarily to fund strategic acquisitions and cover costs related to upcoming convertible notes.
Leadership Insights
Joseph Dziedzic, Integer's President and CEO, stated, "Integer delivered another strong quarter of growth with prominent increases across key financial metrics. Although we foresee some headwinds affecting our 2026 sales, our robust strategy and product development pipeline position us well for continued growth, aiming for above-market organic growth in 2027."
Product Line Performance
In the third quarter of 2025, Integer's product lines exhibited notable performance:
- The Cardio & Vascular segment saw an impressive 15% sales increase due to successful new product launches and strong demand across neurovascular markets.
- Sales in the Cardiac Rhythm Management & Neuromodulation segment increased by 2%, influenced by growth among emerging neuromodulation clients and returning normalized growth patterns in cardiac rhythm management.
- Conversely, the Other Markets segment encountered a 16% decline, primarily due to the strategic exit from the portable medical segment.
Future Projections for 2025
Integer has also provided an optimistic outlook for the full year of 2025:
- Expected sales will range from $1,840 million to $1,854 million, reflecting a 7% to 8% growth rate.
- GAAP operating income is projected between $220 million and $226 million.
- Non-GAAP adjusted operating income is forecasted to be in the range of $319 million to $325 million.
- Adjusted EBITDA is anticipated to be around $398 million to $404 million, underscoring strong operational efficiency.
2026 and 2027 Preliminary Outlook
Looking ahead, Integer is set to navigate potential market fluctuations with a streamlined approach, aiming for:
* Reported sales growth for 2026 predicted to fluctuate between a decrease of 2% to an increase of 2%. * By 2027, the organization is targeting organic sales growth exceeding market average by 200 basis points.
Investor Relations Update
The Company will host a conference call to discuss these results further, scheduled for October 23, 2025. Participants can connect via the company's website or by dialing provided numbers. Full details are available through investor channels.
Frequently Asked Questions
What were Integer's total sales for Q3 2025?
Integer's total sales for Q3 2025 reached $468 million.
How much did the non-GAAP adjusted operating income increase?
The non-GAAP adjusted operating income increased by 14%, amounting to $86 million.
What is the company's outlook for sales in 2025?
The company expects sales to be between $1,840 million to $1,854 million for the full year of 2025.
What segments of Integer's product line saw growth?
The Cardio & Vascular segment had a substantial 15% increase in sales, while the Cardiac Rhythm Management & Neuromodulation segment grew by 2%.
How will Integer handle potential headwinds in 2026?
Integer plans to utilize its robust strategy and product development pipeline to navigate expected headwinds and target growth in subsequent years.
